A Trial of Ribupatide Injection in Participants With Obesity and Knee Osteoarthritis

Inclusion Criteria: \- 1、Voluntarily sign the informed consent form, agree to comply with the protocol requirements, and be willing and able to complete the study; 1. 2、Aged ≥18 years on the date of signing the informed consent form, male or female; 2. 3、BMI ≥28.0 kg/m² at screening; 3. 4、Self-reported dietary and exercise control for 3 months or more prior to screening, and body weight change (difference between maximum and minimum body weight within 3 months) ≤5.0 kg in the 3 months prior to screening; 4. 5、Based on the American College of Rheumatology criteria, the clinical diagnosis is knee osteoarthritis, and the target knee joint X-ray examination shows a K-L grade of 2-3 at screening. Exclusion Criteria: 1. Existence of endocrine diseases that may significantly affect body weight; 2. Existence of any conditions affecting gastric emptying; 3. Known history of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic/treated gallbladder diseases; 4. Known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2); 5. Severe infection, major trauma, or major/medium surgery within 1 month prior to screening; 6. History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening; 7. History of malignancy in any organ system within 5 years prior to screening; 8. Existence or suspicion of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other serious mental illnesses; 9. Known or suspected history of alcohol and/or drug abuse or addiction; 10. Symptoms or signs of acute or chronic hepatitis, or any liver disease other than metabolic dysfunction-associated fatty liver disease; 11. Existence of serious hematologic diseases or any conditions causing hemolysis or red blood cell instability; 12. Existence of autoimmune diseases requiring systemic glucocorticoid or immunosuppressive therapy during the study period; 13. Known or suspected allergy to GLP-1 and/or GIP receptor agonists or their excipients; 14. Participation in any drug or medical device clinical trial within 3 months prior to screening; 15. Blood donation or cumulative blood loss ≥400 mL within 3 months prior to screening, or receipt of blood transfusion within 3 months; 16. Participants with mental incompetence or language impairments that prevent full understanding or participation in the trial process.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.